Abstract:Multiple myeloma (MM), a malignancy of plasma cells, is an incurable disease that is characterized by the neoplastic proliferation of plasma cells leading to extensive skeletal destruction. This includes osteolytic lesions, osteopenia, and pathologic fractures. MM is clinically manifested through bone pain, renal insufficiency, hypercalcemia, anemia, and recurrent infections. Its prevalence and the need for effective treatment underscore the importance of this research. Recent advancements in MM therapy have been significant, particularly with the integration of daratumumab into first-line treatments. The use of daratumumab in regimens such as DRD (Daratumumab, Revlimid, Dexamethasone) and D-RVd (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) represents a paradigm shift in the treatment landscape. GRIFFIN and CASSIOPEIA trials have highlighted the efficacy of these regimens, particularly in prolonging progression-free survival and deepening patient responses. The shift from older regimens like MPV (Melphalan, Prednisone, Velcade) to more effective ones like DRD and RVD has been pivotal in treatment strategies. This review also focuses on the potential of Chimeric Antigen Receptor T-cell therapy and bispecific antibodies in MM. CAR-T therapy, which has shown success in other hematological malignancies, is being explored for its ability to specifically target MM cells. The latest clinical trials and research findings are analyzed to evaluate the efficacy and challenges of CAR-T therapy in MM. Additionally, the role of bispecific antibodies, which are designed to bind both cancer cells and T cells, is explored. These antibodies offer a unique mechanism that could complement the effects of CAR-T therapy.

Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma——Review

Emerging agents and regimens for multiple myeloma

Multiple myeloma, immunotherapy and minimal residual disease

[Recent topics in IMiDs and cereblon]

Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma

Therapeutic progress in relapsed/refractory multiple myeloma

Recent advance of small-molecule drugs for clinical treatment of multiple myeloma

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

Current status of bispecific antibodies and CAR-T therapies in multiple myeloma

[Research progress in targeting GPRC5D for the treatment of multiple myeloma]

Current Advances in Chimeric Antigen Receptor T-cell Therapy for Refractory/relapsed Multiple Myeloma.

Recent advances in the treatment of multiple myeloma: a brief review

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Advances in Research on Potential Inhibitors of Multiple Myeloma

Progress in the research and treatment of relapsed and refractory multiple myeloma

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma